Literature DB >> 19652360

Tumor emergence is sensed by self-specific CD44hi memory Tregs that create a dominant tolerogenic environment for tumors in mice.

Guillaume Darrasse-Jèze1, Anne-Sophie Bergot, Aurélie Durgeau, Fabienne Billiard, Benoît L Salomon, José L Cohen, Bertrand Bellier, Katrina Podsypanina, David Klatzmann.   

Abstract

Early responses of Tregs and effector T cells (Teffs) to their first encounter with tumor cells have been poorly characterized. Here we have shown, in both implanted and in situ-induced mouse tumor models, that the appearance of tumor cells is immediately sensed by CD44hi memory Tregs that are specific for self antigens. The rapid response of these Tregs preceded and prevented activation of naive antitumor Teffs. The relative speed of the Treg versus the Teff response within the first 2-4 days determined the outcome of the antitumor immune response: tolerance or rejection. If antitumor memory Teffs were present at the time of tumor emergence, both Tregs and Teffs were recruited and activated with memory kinetics; however, the Tregs were unable to control the Teffs, which eradicated the tumor cells. This balance between effector and regulatory responses did not depend on the number of Tregs and Teffs, but rather on their memory status. Thus, in the natural setting, dominant tolerogenic immunosurveillance by self-specific memory Tregs protects tumors, just as it protects normal tissues. More generally, our results reveal that the timing of Treg and Teff engagement, determined by their memory status, is an important mode of regulation of immune responses.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19652360      PMCID: PMC2735938          DOI: 10.1172/JCI36628

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  76 in total

1.  Effector memory T cells, early metastasis, and survival in colorectal cancer.

Authors:  Franck Pagès; Anne Berger; Matthieu Camus; Fatima Sanchez-Cabo; Anne Costes; Robert Molidor; Bernhard Mlecnik; Amos Kirilovsky; Malin Nilsson; Diane Damotte; Tchao Meatchi; Patrick Bruneval; Paul-Henri Cugnenc; Zlatko Trajanoski; Wolf-Herman Fridman; Jérôme Galon
Journal:  N Engl J Med       Date:  2005-12-22       Impact factor: 91.245

2.  The expression of the regulatory T cell-specific forkhead box transcription factor FoxP3 is associated with poor prognosis in ovarian cancer.

Authors:  Dominik Wolf; Anna M Wolf; Holger Rumpold; Heidi Fiegl; Alain G Zeimet; Elisabeth Muller-Holzner; Martina Deibl; Guenther Gastl; Eberhard Gunsilius; Christian Marth
Journal:  Clin Cancer Res       Date:  2005-12-01       Impact factor: 12.531

3.  Sporadic immunogenic tumours avoid destruction by inducing T-cell tolerance.

Authors:  Gerald Willimsky; Thomas Blankenstein
Journal:  Nature       Date:  2005-09-01       Impact factor: 49.962

Review 4.  CD69 and regulation of the immune function.

Authors:  R Marzio; J Mauël; S Betz-Corradin
Journal:  Immunopharmacol Immunotoxicol       Date:  1999-08       Impact factor: 2.730

5.  Naive regulatory T cells: a novel subpopulation defined by resistance toward CD95L-mediated cell death.

Authors:  Benedikt Fritzsching; Nina Oberle; Eva Pauly; Robert Geffers; Jan Buer; Johannes Poschl; Peter Krammer; Otwin Linderkamp; Elisabeth Suri-Payer
Journal:  Blood       Date:  2006-07-25       Impact factor: 22.113

6.  Regulatory T cells suppress tumor-specific CD8 T cell cytotoxicity through TGF-beta signals in vivo.

Authors:  Mei-Ling Chen; Mikaël J Pittet; Leonid Gorelik; Richard A Flavell; Ralph Weissleder; Harald von Boehmer; Khashayarsha Khazaie
Journal:  Proc Natl Acad Sci U S A       Date:  2004-12-27       Impact factor: 11.205

7.  Peripheral tolerance to an islet cell-specific hemagglutinin transgene affects both CD4+ and CD8+ T cells.

Authors:  D Lo; J Freedman; S Hesse; R D Palmiter; R L Brinster; L A Sherman
Journal:  Eur J Immunol       Date:  1992-04       Impact factor: 5.532

8.  Human CD4+CD25+ regulatory T cells share equally complex and comparable repertoires with CD4+CD25- counterparts.

Authors:  Kimberly A Kasow; Xiaohua Chen; James Knowles; David Wichlan; Rupert Handgretinger; Janice M Riberdy
Journal:  J Immunol       Date:  2004-05-15       Impact factor: 5.422

9.  Tumor cells convert immature myeloid dendritic cells into TGF-beta-secreting cells inducing CD4+CD25+ regulatory T cell proliferation.

Authors:  François Ghiringhelli; Pierre E Puig; Stephan Roux; Arnaud Parcellier; Elise Schmitt; Eric Solary; Guido Kroemer; François Martin; Bruno Chauffert; Laurence Zitvogel
Journal:  J Exp Med       Date:  2005-09-26       Impact factor: 14.307

10.  Developmental stage, phenotype, and migration distinguish naive- and effector/memory-like CD4+ regulatory T cells.

Authors:  Jochen Huehn; Kerstin Siegmund; Joachim C U Lehmann; Christiane Siewert; Uta Haubold; Markus Feuerer; Gudrun F Debes; Joerg Lauber; Oliver Frey; Grzegorz K Przybylski; Uwe Niesner; Maurus de la Rosa; Christian A Schmidt; Rolf Bräuer; Jan Buer; Alexander Scheffold; Alf Hamann
Journal:  J Exp Med       Date:  2004-02-02       Impact factor: 14.307

View more
  54 in total

Review 1.  The Role of Regulatory T Cells in Mesothelioma.

Authors:  Demelza J Ireland; Haydn T Kissick; Manfred W Beilharz
Journal:  Cancer Microenviron       Date:  2012-02-01

2.  S1PR1 is crucial for accumulation of regulatory T cells in tumors via STAT3.

Authors:  Saul J Priceman; Shudan Shen; Lin Wang; Jiehui Deng; Chanyu Yue; Maciej Kujawski; Hua Yu
Journal:  Cell Rep       Date:  2014-03-13       Impact factor: 9.423

Review 3.  Guidance factors orchestrating regulatory T cell positioning in tissues during development, homeostasis, and response.

Authors:  Thorsten R Mempel; Francesco Marangoni
Journal:  Immunol Rev       Date:  2019-05       Impact factor: 12.988

4.  Dynamic Treg interactions with intratumoral APCs promote local CTL dysfunction.

Authors:  Christian A Bauer; Edward Y Kim; Francesco Marangoni; Esteban Carrizosa; Natalie M Claudio; Thorsten R Mempel
Journal:  J Clin Invest       Date:  2014-05-08       Impact factor: 14.808

5.  TGF-β and VEGF cooperatively control the immunotolerant tumor environment and the efficacy of cancer immunotherapies.

Authors:  Tristan Courau; Djamel Nehar-Belaid; Laura Florez; Béatrice Levacher; Thomas Vazquez; Faustine Brimaud; Bertrand Bellier; David Klatzmann
Journal:  JCI Insight       Date:  2016-06-16

6.  Primary 4T1 tumor resection provides critical "window of opportunity" for immunotherapy.

Authors:  Anahit Ghochikyan; Arpine Davtyan; Armine Hovakimyan; Hayk Davtyan; Anna Poghosyan; Alexander Bagaev; Ravshan I Ataullakhanov; Edward L Nelson; Michael G Agadjanyan
Journal:  Clin Exp Metastasis       Date:  2013-10-06       Impact factor: 5.150

7.  Low-dose cyclophosphamide synergizes with dendritic cell-based immunotherapy in antitumor activity.

Authors:  Joris D Veltman; Margaretha E H Lambers; Menno van Nimwegen; Sanne de Jong; Rudi W Hendriks; Henk C Hoogsteden; Joachim G J V Aerts; Joost P J J Hegmans
Journal:  J Biomed Biotechnol       Date:  2010-05-23

8.  Intratumoral convergence of the TCR repertoires of effector and Foxp3+ CD4+ T cells.

Authors:  Michal Kuczma; Magdalena Kopij; Iwona Pawlikowska; Cong-Yi Wang; Grzegorz A Rempala; Piotr Kraj
Journal:  PLoS One       Date:  2010-10-26       Impact factor: 3.240

9.  Antigen quality determines the efficiency of antitumor immune responses generated in the absence of regulatory T cells.

Authors:  A-S Bergot; A Durgeau; B Levacher; B M Colombo; J L Cohen; D Klatzmann
Journal:  Cancer Gene Ther       Date:  2010-05-14       Impact factor: 5.987

Review 10.  CRP identifies homeostatic immune oscillations in cancer patients: a potential treatment targeting tool?

Authors:  Brendon J Coventry; Martin L Ashdown; Michael A Quinn; Svetomir N Markovic; Steven L Yatomi-Clarke; Andrew P Robinson
Journal:  J Transl Med       Date:  2009-11-30       Impact factor: 5.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.